Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach.

Craig SG, Anderson LA, Schache AG, Moran M, Graham L, Currie K, Rooney K, Robinson M, Upile NS, Brooker R, Mesri M, Bingham V, McQuaid S, Jones T, McCance DJ, Salto-Tellez M, McDade SS, James JA.

Br J Cancer. 2019 Mar 20. doi: 10.1038/s41416-019-0414-9. [Epub ahead of print]

PMID:
30890775
2.

Hyper Acute Quadriplegia with Chronic Lead Toxicity; a Case Report.

Mesri M, Najari F, Baradaran Kayal I, Najari D.

Emerg (Tehran). 2018;6(1):e44. Epub 2018 Jul 15.

3.

Chinese Herbal Medicine Glycyrrhiza inflataReduces Aβ Aggregation and Exerts Neuroprotection through Anti-Oxidation and Anti-Inflammation.

Chiu YJ, Lee CM, Lin TH, Lin HY, Lee SY, Mesri M, Chang KH, Lin JY, Lee-Chen GJ, Chen CM.

Am J Chin Med. 2018 Oct 4:1-25. doi: 10.1142/S0192415X18500799. [Epub ahead of print]

PMID:
30284464
4.

Anti-α-Gal antibodies detected by novel neoglycoproteins as a diagnostic tool for Old World cutaneous leishmaniasis caused by Leishmania major.

Subramaniam KS, Austin V, Schocker NS, Montoya AL, Anderson MS, Ashmus RA, Mesri M, Al-Salem W, Almeida IC, Michael K, Acosta-Serrano A.

Parasitology. 2018 Nov;145(13):1758-1764. doi: 10.1017/S0031182018000860. Epub 2018 Jun 14.

PMID:
29898796
5.

Abstract ID: 247 Patient specific scatter reduction in SIRT gamma camera images.

Matthies P, Mesri M, Pinto FA, Wuestemann J, Grosser O.

Phys Med. 2018 Jan;45 Suppl 1:S5-S6. doi: 10.1016/j.ejmp.2017.11.035.

PMID:
29413858
6.

Accelerated rigor mortis: A case letter.

Mesri M, Behzadnia M, Dorooshi G.

J Res Med Sci. 2017 Nov 28;22:126. doi: 10.4103/jrms.JRMS_599_17. eCollection 2017. No abstract available.

7.

Corrigendum: Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.

Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, Wyczalkowski MA, Erdmann-Gilmore P, Snider JE, Hoog J, Singh P, Niu B, Guo Z, Sun SQ, Sanati S, Kawaler E, Wang X, Scott A, Ye K, McLellan MD, Wendl MC, Malovannaya A, Held JM, Gillette MA, Fenyö D, Kinsinger CR, Mesri M, Rodriguez H, Davies SR, Perou CM, Ma C, Townsend RR, Chen X, Carr SA, Ellis MJ, Ding L.

Nat Commun. 2017 Apr 25;8:15479. doi: 10.1038/ncomms15479. No abstract available.

8.

Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.

Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, Wyczalkowski MA, Erdmann-Gilmore P, Snider JE, Hoog J, Singh P, Niu B, Guo Z, Sun SQ, Sanati S, Kawaler E, Wang X, Scott A, Ye K, McLellan MD, Wendl MC, Malovannaya A, Held JM, Gillette MA, Fenyö D, Kinsinger CR, Mesri M, Rodriguez H, Davies SR, Perou CM, Ma C, Reid Townsend R, Chen X, Carr SA, Ellis MJ, Ding L.

Nat Commun. 2017 Mar 28;8:14864. doi: 10.1038/ncomms14864.

9.

Proteome Profiling Outperforms Transcriptome Profiling for Coexpression Based Gene Function Prediction.

Wang J, Ma Z, Carr SA, Mertins P, Zhang H, Zhang Z, Chan DW, Ellis MJ, Townsend RR, Smith RD, McDermott JE, Chen X, Paulovich AG, Boja ES, Mesri M, Kinsinger CR, Rodriguez H, Rodland KD, Liebler DC, Zhang B.

Mol Cell Proteomics. 2017 Jan;16(1):121-134. doi: 10.1074/mcp.M116.060301. Epub 2016 Nov 11.

10.

Proteogenomics connects somatic mutations to signalling in breast cancer.

Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, Kawaler E, Mundt F, Krug K, Tu Z, Lei JT, Gatza ML, Wilkerson M, Perou CM, Yellapantula V, Huang KL, Lin C, McLellan MD, Yan P, Davies SR, Townsend RR, Skates SJ, Wang J, Zhang B, Kinsinger CR, Mesri M, Rodriguez H, Ding L, Paulovich AG, Fenyö D, Ellis MJ, Carr SA; NCI CPTAC.

Nature. 2016 Jun 2;534(7605):55-62. doi: 10.1038/nature18003. Epub 2016 May 25.

11.

Using the CPTAC Assay Portal to Identify and Implement Highly Characterized Targeted Proteomics Assays.

Whiteaker JR, Halusa GN, Hoofnagle AN, Sharma V, MacLean B, Yan P, Wrobel JA, Kennedy J, Mani DR, Zimmerman LJ, Meyer MR, Mesri M, Boja E, Carr SA, Chan DW, Chen X, Chen J, Davies SR, Ellis MJ, Fenyö D, Hiltke T, Ketchum KA, Kinsinger C, Kuhn E, Liebler DC, Liu T, Loss M, MacCoss MJ, Qian WJ, Rivers R, Rodland KD, Ruggles KV, Scott MG, Smith RD, Thomas S, Townsend RR, Whiteley G, Wu C, Zhang H, Zhang Z, Rodriguez H, Paulovich AG.

Methods Mol Biol. 2016;1410:223-36. doi: 10.1007/978-1-4939-3524-6_13.

12.

A Description of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) Common Data Analysis Pipeline.

Rudnick PA, Markey SP, Roth J, Mirokhin Y, Yan X, Tchekhovskoi DV, Edwards NJ, Thangudu RR, Ketchum KA, Kinsinger CR, Mesri M, Rodriguez H, Stein SE.

J Proteome Res. 2016 Mar 4;15(3):1023-32. doi: 10.1021/acs.jproteome.5b01091. Epub 2016 Feb 25.

13.

Associations of Matrix Metalloproteinase-9 and Tissue Inhibitory Factor-1 Polymorphisms With Parkinson Disease in Taiwan.

Chen YC, Wu YR, Mesri M, Chen CM.

Medicine (Baltimore). 2016 Feb;95(5):e2672. doi: 10.1097/MD.0000000000002672.

14.

Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays.

Hoofnagle AN, Whiteaker JR, Carr SA, Kuhn E, Liu T, Massoni SA, Thomas SN, Townsend RR, Zimmerman LJ, Boja E, Chen J, Crimmins DL, Davies SR, Gao Y, Hiltke TR, Ketchum KA, Kinsinger CR, Mesri M, Meyer MR, Qian WJ, Schoenherr RM, Scott MG, Shi T, Whiteley GR, Wrobel JA, Wu C, Ackermann BL, Aebersold R, Barnidge DR, Bunk DM, Clarke N, Fishman JB, Grant RP, Kusebauch U, Kushnir MM, Lowenthal MS, Moritz RL, Neubert H, Patterson SD, Rockwood AL, Rogers J, Singh RJ, Van Eyk JE, Wong SH, Zhang S, Chan DW, Chen X, Ellis MJ, Liebler DC, Rodland KD, Rodriguez H, Smith RD, Zhang Z, Zhang H, Paulovich AG.

Clin Chem. 2016 Jan;62(1):48-69. doi: 10.1373/clinchem.2015.250563.

15.

Reproducibility of Differential Proteomic Technologies in CPTAC Fractionated Xenografts.

Tabb DL, Wang X, Carr SA, Clauser KR, Mertins P, Chambers MC, Holman JD, Wang J, Zhang B, Zimmerman LJ, Chen X, Gunawardena HP, Davies SR, Ellis MJ, Li S, Townsend RR, Boja ES, Ketchum KA, Kinsinger CR, Mesri M, Rodriguez H, Liu T, Kim S, McDermott JE, Payne SH, Petyuk VA, Rodland KD, Smith RD, Yang F, Chan DW, Zhang B, Zhang H, Zhang Z, Zhou JY, Liebler DC.

J Proteome Res. 2016 Mar 4;15(3):691-706. doi: 10.1021/acs.jproteome.5b00859. Epub 2015 Dec 22.

16.

Fingerprints: A simple method for Screening Hemophilic Patients.

Jamalian M, Mesri M, Vishteh HR, Solhi H, Salehpour R.

Bangladesh Med Res Counc Bull. 2014 Aug;40(2):85-8.

PMID:
26415346
17.

Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium.

Birse CE, Lagier RJ, FitzHugh W, Pass HI, Rom WN, Edell ES, Bungum AO, Maldonado F, Jett JR, Mesri M, Sult E, Joseloff E, Li A, Heidbrink J, Dhariwal G, Danis C, Tomic JL, Bruce RJ, Moore PA, He T, Lewis ME, Ruben SM.

Clin Proteomics. 2015 Jul 16;12(1):18. doi: 10.1186/s12014-015-9090-9. eCollection 2015.

18.

Large-Scale Interlaboratory Study to Develop, Analytically Validate and Apply Highly Multiplexed, Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma.

Abbatiello SE, Schilling B, Mani DR, Zimmerman LJ, Hall SC, MacLean B, Albertolle M, Allen S, Burgess M, Cusack MP, Gosh M, Hedrick V, Held JM, Inerowicz HD, Jackson A, Keshishian H, Kinsinger CR, Lyssand J, Makowski L, Mesri M, Rodriguez H, Rudnick P, Sadowski P, Sedransk N, Shaddox K, Skates SJ, Kuhn E, Smith D, Whiteaker JR, Whitwell C, Zhang S, Borchers CH, Fisher SJ, Gibson BW, Liebler DC, MacCoss MJ, Neubert TA, Paulovich AG, Regnier FE, Tempst P, Carr SA.

Mol Cell Proteomics. 2015 Sep;14(9):2357-74. doi: 10.1074/mcp.M114.047050. Epub 2015 Feb 18.

19.

Linking cancer genome to proteome: NCI's investment into proteogenomics.

Rivers RC, Kinsinger C, Boja ES, Hiltke T, Mesri M, Rodriguez H.

Proteomics. 2014 Dec;14(23-24):2633-6. doi: 10.1002/pmic.201400193. Epub 2014 Oct 18.

PMID:
25187343
20.

CPTAC Assay Portal: a repository of targeted proteomic assays.

Whiteaker JR, Halusa GN, Hoofnagle AN, Sharma V, MacLean B, Yan P, Wrobel JA, Kennedy J, Mani DR, Zimmerman LJ, Meyer MR, Mesri M, Rodriguez H; Clinical Proteomic Tumor Analysis Consortium (CPTAC), Paulovich AG.

Nat Methods. 2014 Jul;11(7):703-4. doi: 10.1038/nmeth.3002. No abstract available.

21.

Advances in Proteomic Technologies and Its Contribution to the Field of Cancer.

Mesri M.

Adv Med. 2014;2014:238045. doi: 10.1155/2014/238045. Epub 2014 Sep 7. Review.

22.

Identification and characterization of angiogenesis targets through proteomic profiling of endothelial cells in human cancer tissues.

Mesri M, Birse C, Heidbrink J, McKinnon K, Brand E, Bermingham CL, Feild B, Fitzhugh W, He T, Ruben S, Moore PA.

PLoS One. 2013 Nov 13;8(11):e78885. doi: 10.1371/journal.pone.0078885. eCollection 2013.

23.

Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium.

Ellis MJ, Gillette M, Carr SA, Paulovich AG, Smith RD, Rodland KK, Townsend RR, Kinsinger C, Mesri M, Rodriguez H, Liebler DC; Clinical Proteomic Tumor Analysis Consortium (CPTAC).

Cancer Discov. 2013 Oct;3(10):1108-12. doi: 10.1158/2159-8290.CD-13-0219.

24.

Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies.

Skates SJ, Gillette MA, LaBaer J, Carr SA, Anderson L, Liebler DC, Ransohoff D, Rifai N, Kondratovich M, Težak Ž, Mansfield E, Oberg AL, Wright I, Barnes G, Gail M, Mesri M, Kinsinger CR, Rodriguez H, Boja ES.

J Proteome Res. 2013 Dec 6;12(12):5383-94. doi: 10.1021/pr400132j. Epub 2013 Oct 28.

25.

BTNL8, a butyrophilin-like molecule that costimulates the primary immune response.

Chapoval AI, Smithson G, Brunick L, Mesri M, Boldog FL, Andrew D, Khramtsov NV, Feshchenko EA, Starling GC, Mezes PS.

Mol Immunol. 2013 Dec;56(4):819-28. doi: 10.1016/j.molimm.2013.08.003.

PMID:
24036152
26.

Design, implementation and multisite evaluation of a system suitability protocol for the quantitative assessment of instrument performance in liquid chromatography-multiple reaction monitoring-MS (LC-MRM-MS).

Abbatiello SE, Mani DR, Schilling B, Maclean B, Zimmerman LJ, Feng X, Cusack MP, Sedransk N, Hall SC, Addona T, Allen S, Dodder NG, Ghosh M, Held JM, Hedrick V, Inerowicz HD, Jackson A, Keshishian H, Kim JW, Lyssand JS, Riley CP, Rudnick P, Sadowski P, Shaddox K, Smith D, Tomazela D, Wahlander A, Waldemarson S, Whitwell CA, You J, Zhang S, Kinsinger CR, Mesri M, Rodriguez H, Borchers CH, Buck C, Fisher SJ, Gibson BW, Liebler D, Maccoss M, Neubert TA, Paulovich A, Regnier F, Skates SJ, Tempst P, Wang M, Carr SA.

Mol Cell Proteomics. 2013 Sep;12(9):2623-39. doi: 10.1074/mcp.M112.027078. Epub 2013 May 20.

27.

Realizing individualized medicine: the road to translating proteomics from the laboratory to the clinic.

Rahbar A, Rivers R, Boja E, Kinsinger C, Mesri M, Hiltke T, Rodriguez H.

Per Med. 2011 Jan;8(1):45-57. doi: 10.2217/pme.10.76.

PMID:
29768786
28.

A synopsis of the 3rd annual Cancer Proteomics Conference.

Mesri M, Kinsinger C, Boja E, Hiltke T, Rahbar A, Rivers R, Rodriguez H.

Expert Rev Proteomics. 2010 Dec;7(6):815-7. doi: 10.1586/epr.10.95.

PMID:
21142883
29.

Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective.

Rodriguez H, Rivers R, Kinsinger C, Mesri M, Hiltke T, Rahbar A, Boja E.

Proteomics Clin Appl. 2010 Dec;4(12):904-14. doi: 10.1002/prca.201000057. Epub 2010 Nov 22. Review.

30.

Restructuring proteomics through verification.

Boja E, Rivers R, Kinsinger C, Mesri M, Hiltke T, Rahbar A, Rodriguez H.

Biomark Med. 2010 Dec;4(6):799-803. doi: 10.2217/bmm.10.92. Review.

31.

Evolution of clinical proteomics and its role in medicine.

Boja E, Hiltke T, Rivers R, Kinsinger C, Rahbar A, Mesri M, Rodriguez H.

J Proteome Res. 2011 Jan 7;10(1):66-84. doi: 10.1021/pr100532g. Epub 2010 Sep 16. Review.

PMID:
20715861
32.

Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics.

Rodriguez H, Tezak Z, Mesri M, Carr SA, Liebler DC, Fisher SJ, Tempst P, Hiltke T, Kessler LG, Kinsinger CR, Philip R, Ransohoff DF, Skates SJ, Regnier FE, Anderson NL, Mansfield E; Workshop Participants.

Clin Chem. 2010 Feb;56(2):237-43. doi: 10.1373/clinchem.2009.136416. Epub 2009 Dec 10. Review.

33.

Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration.

Regnier FE, Skates SJ, Mesri M, Rodriguez H, Tezak Z, Kondratovich MV, Alterman MA, Levin JD, Roscoe D, Reilly E, Callaghan J, Kelm K, Brown D, Philip R, Carr SA, Liebler DC, Fisher SJ, Tempst P, Hiltke T, Kessler LG, Kinsinger CR, Ransohoff DF, Mansfield E, Anderson NL.

Clin Chem. 2010 Feb;56(2):165-71. doi: 10.1373/clinchem.2009.140087. Epub 2009 Dec 10.

34.

Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry.

Tabb DL, Vega-Montoto L, Rudnick PA, Variyath AM, Ham AJ, Bunk DM, Kilpatrick LE, Billheimer DD, Blackman RK, Cardasis HL, Carr SA, Clauser KR, Jaffe JD, Kowalski KA, Neubert TA, Regnier FE, Schilling B, Tegeler TJ, Wang M, Wang P, Whiteaker JR, Zimmerman LJ, Fisher SJ, Gibson BW, Kinsinger CR, Mesri M, Rodriguez H, Stein SE, Tempst P, Paulovich AG, Liebler DC, Spiegelman C.

J Proteome Res. 2010 Feb 5;9(2):761-76. doi: 10.1021/pr9006365.

35.

Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance.

Paulovich AG, Billheimer D, Ham AJ, Vega-Montoto L, Rudnick PA, Tabb DL, Wang P, Blackman RK, Bunk DM, Cardasis HL, Clauser KR, Kinsinger CR, Schilling B, Tegeler TJ, Variyath AM, Wang M, Whiteaker JR, Zimmerman LJ, Fenyo D, Carr SA, Fisher SJ, Gibson BW, Mesri M, Neubert TA, Regnier FE, Rodriguez H, Spiegelman C, Stein SE, Tempst P, Liebler DC.

Mol Cell Proteomics. 2010 Feb;9(2):242-54. doi: 10.1074/mcp.M900222-MCP200. Epub 2009 Oct 26.

36.

Performance metrics for liquid chromatography-tandem mass spectrometry systems in proteomics analyses.

Rudnick PA, Clauser KR, Kilpatrick LE, Tchekhovskoi DV, Neta P, Blonder N, Billheimer DD, Blackman RK, Bunk DM, Cardasis HL, Ham AJ, Jaffe JD, Kinsinger CR, Mesri M, Neubert TA, Schilling B, Tabb DL, Tegeler TJ, Vega-Montoto L, Variyath AM, Wang M, Wang P, Whiteaker JR, Zimmerman LJ, Carr SA, Fisher SJ, Gibson BW, Paulovich AG, Regnier FE, Rodriguez H, Spiegelman C, Tempst P, Liebler DC, Stein SE.

Mol Cell Proteomics. 2010 Feb;9(2):225-41. doi: 10.1074/mcp.M900223-MCP200. Epub 2009 Oct 16.

37.

Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma.

Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, Spiegelman CH, Zimmerman LJ, Ham AJ, Keshishian H, Hall SC, Allen S, Blackman RK, Borchers CH, Buck C, Cardasis HL, Cusack MP, Dodder NG, Gibson BW, Held JM, Hiltke T, Jackson A, Johansen EB, Kinsinger CR, Li J, Mesri M, Neubert TA, Niles RK, Pulsipher TC, Ransohoff D, Rodriguez H, Rudnick PA, Smith D, Tabb DL, Tegeler TJ, Variyath AM, Vega-Montoto LJ, Wahlander A, Waldemarson S, Wang M, Whiteaker JR, Zhao L, Anderson NL, Fisher SJ, Liebler DC, Paulovich AG, Regnier FE, Tempst P, Carr SA.

Nat Biotechnol. 2009 Jul;27(7):633-41. doi: 10.1038/nbt.1546. Epub 2009 Jun 28. Erratum in: Nat Biotechnol. 2009 Sep;27(9):864.

38.

Use of an immunoaffinity-mass spectrometry-based approach for the quantification of protein biomarkers from serum samples of lung cancer patients.

Nicol GR, Han M, Kim J, Birse CE, Brand E, Nguyen A, Mesri M, FitzHugh W, Kaminker P, Moore PA, Ruben SM, He T.

Mol Cell Proteomics. 2008 Oct;7(10):1974-82. doi: 10.1074/mcp.M700476-MCP200. Epub 2008 Apr 3.

39.

Gastrointestinal and urinary tract bleeding in methanol toxicity.

Mostafazadeh B, Talaie H, Mahdavinejad A, Mesri M, Emanhadi M.

BMJ Case Rep. 2008;2008:bcr0820080619. doi: 10.1136/bcr.08.2008.0619. Epub 2008 Nov 20.

40.

Inhibition of in vitro and in vivo T cell responses by recombinant human Tim-1 extracellular domain proteins.

Mesri M, Smithson G, Ghatpande A, Chapoval A, Shenoy S, Boldog F, Hackett C, Pena CE, Burgess C, Bendele A, Shimkets RA, Starling GC.

Int Immunol. 2006 Mar;18(3):473-84. Epub 2006 Feb 15.

PMID:
16481347
41.

Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis.

Alvarez E, Fey EG, Valax P, Yim Z, Peterson JD, Mesri M, Jeffers M, Dindinger M, Twomlow N, Ghatpande A, LaRochelle WJ, Sonis ST, Lichenstein HS.

Clin Cancer Res. 2003 Aug 15;9(9):3454-61.

42.

Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis.

Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC.

Clin Cancer Res. 2003 Jul;9(7):2683-92.

43.

Cancer gene therapy using a survivin mutant adenovirus.

Mesri M, Wall NR, Li J, Kim RW, Altieri DC.

J Clin Invest. 2001 Oct;108(7):981-90.

44.

Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting.

Mesri M, Morales-Ruiz M, Ackermann EJ, Bennett CF, Pober JS, Sessa WC, Altieri DC.

Am J Pathol. 2001 May;158(5):1757-65.

45.

Interleukin-11 up-regulates survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway.

Mahboubi K, Li F, Plescia J, Kirkiles-Smith NC, Mesri M, Du Y, Carroll JM, Elias JA, Altieri DC, Pober JS.

Lab Invest. 2001 Mar;81(3):327-34.

PMID:
11310826
46.

A functional analysis of a natural variant of intercellular adhesion molecule-1 (ICAM-1Kilifi).

Craig A, Fernandez-Reyes D, Mesri M, McDowall A, Altieri DC, Hogg N, Newbold C.

Hum Mol Genet. 2000 Mar 1;9(4):525-30.

PMID:
10699175
47.

Control of apoptosis during angiogenesis by survivin expression in endothelial cells.

O'Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, Li F, Nath AK, Pober JS, Altieri DC.

Am J Pathol. 2000 Feb;156(2):393-8.

49.

Endothelial cell activation by leukocyte microparticles.

Mesri M, Altieri DC.

J Immunol. 1998 Oct 15;161(8):4382-7.

Supplemental Content

Support Center